newsfilter
← Latest News
GlobeNewswire·

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK and VIENNA, Austria,